By Phil Newman – Longevity.Technology
Longevity.Technology CEO shares his outlook for longevity investing, exploring longevity domains and categories and the clinical stages of longevity biotechs.
Last year, I was invited to share my outlook on the longevity investment landscape at a key summit in Berlin. The Rejuvenation Startup Summit brings together startups, members of the longevity venture capital / investor ecosystem, and researchers interested in founding or joining a startup – all aiming to create therapies to vastly extend the healthy human lifespan.
The Summit may be a few months behind us now, having occurred in October 2022, but the influence of this important meeting continues.
In fact, only earlier this week, we published news about Cellvie closing $5.5 million to accelerate development of Therapeutic Mitochondria Transplantation, and the team at Cyclarity continue to accelerate progress of their novel cyclodextrin therapy for atherosclerosis.
